Overview
STATEMENT OF NEED
Of the estimated 74,200 new cases of non-Hodgkin lymphoma each year in the United States, approximately 22% are FL, an indolent, difficult-to-treat B-cell malignancy (ACS, 2019; NCCN, 2019). Most patients are diagnosed at an average age of 63 years (NCI, 2019). Despite the introduction of novel therapies during the past decade, complications such as delayed presentation and treatment and evolving disease subtypes continue to hamper patient outcomes, and multiple recurrences with available therapies are common (NCCN, 2019). Currently, allogeneic hematopoietic stem cell transplant is the only curative therapeutic modality for relapsed/refractory disease. However, the risk for comorbidities and secondary cancers limits the utility of this treatment upfront. Further research is required to determine the optimal timing and role of transplant and novel therapies to keep the remission rate among FL patients high and durable (NCCN, 2019).
TARGET AUDIENCE
Community oncologists, hematologists, pathologists, oncology advanced practitioners, and other health care professionals involved in the treatment of patients with follicular lymphoma.
LEARNING OBJECTIVES
Upon completion of this activity, participants should be able to:
- Evaluate emerging efficacy and safety data on novel therapeutic approaches for patients with relapsed/refractory FL
- Discuss the implications of POD24 status in therapeutic decision making for patients with relapsed/refractory FL
- Apply strategies to optimize treatment experiences and outcomes for patients with relapsed/refractory FL
FACULTY
Loretta Nastoupil, MD
Assistant Professor of Medicine
MD Anderson Cancer Center
Reem Karmali, MD, MS
Assistant Professor of Medicine
Northwestern Memorial Hospital
Francisco Vega, MD, PhD
Professor of Pathology
Lymphoma Section Head
REGISTRATION
There is no fee to participate in or claim CME credit for this activity.
Provided by
Physicians
i3 Health is accredited by the American Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
i3 Health designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
By providing this information, participants are agreeing to allow i3 Health to share this information with the ACCME.
ONCC RECERTIFICATION
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points.
ONCC review is only for designating content to be used for recertification points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of NCPD to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification may be used in relation to the program.
OCN®, CPHON®, CBCN®, AOCNP®, AOCNS®, and BMTCN® renewal candidates may apply 1 ILNA point toward:
- Care Continuum
- Diagnosis and Staging
- Oncology Nursing Practice
- Palliative Care
- Professional Practice
- Scientific Basis for Practice
- Survivorship
- Symptom Management
- Treatment
Please note that some of the course content applies to multiple content areas. The numerical value above indicates the maximum amount of points that can be claimed in each domain. The total amount of ILNA points claimed may not exceed the total amount of NCPD awarded from this course.
DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH COMMERCIAL INTERESTS
i3 Health endorses the standards of the ACCME and ANCC that require everyone in a position to control the content of a CME activity to disclose all financial relationships with commercial interests that are related to the content of the CME activity. CME activities must be balanced, independent of commercial bias, and promote improvements or quality in health care. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.
A conflict of interest is created when an individual has an opportunity to affect CME content about products or services of a commercial interest with which he/she has a financial relationship, which therefore may bias their opinions and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits.
i3 Health will identify, review, and resolve all conflicts of interest that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. i3 Health does not endorse any products or services.
Relevant financial relationships exist between the following individuals and commercial interests:
The i3 Health planners, reviewers, and managers have nothing to disclose.
Loretta J. Nastoupil, MD discloses that she has served on the advisory board/panel for Celgene, Genentech, Kite/Gilead, Novartis, Pfizer, and TG Therapeutics and has received grants/research support from Celgene, Epizyme, Genentech, Merck, Novartis, and Pfizer.
Reem Karmali, MD discloses that she has served on the advisory board/panel for Bristol Myers Squibb/Celgene, Karyopharm, and Kite/Gilead, and has served on the speaker's bureau for AstraZeneca, BeiGene, and Kite/Gilead, and has received grants/research support from Bristol Myers Squibb/Celgene, Kite/Gilead, and Takeda.
Francisco Vega, MD, PhD has no commercial relationships to disclose.
INSTRUCTIONS TO RECEIVE CREDIT
In order to receive credit for this activity, participants must:
- Take the pretest
- Watch the video
- Pass the posttest with a score of ≥80%
- Complete the activity evaluation
- Download or print their Certificate of Credit
UNAPPROVED USE DISCLOSURE
i3 Health requires CME faculty (speakers) to disclose to attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved), as well as any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling.
This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.
DISCLAIMER
The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.
COMMERCIAL SUPPORT
This activity is supported by an independent educational grant from Epizyme.
Aggregate participant data will be shared with commercial supporters of this activity.
CONTACT INFORMATION
Technical queries or questions regarding activity credit should be directed to i3 Health at This email address is being protected from spambots. You need JavaScript enabled to view it..